Latest News

TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.

Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.

Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.

TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.

TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.

Your daily dose of the clinical news you may have missed.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.